Palisade: Positive Preclinical Data in Crohn’s & Colitis

 – Preclinical data demonstrated PALI-2108 to be safe and well tolerated

– PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure

– Company advancing PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) toward Phase 1 clinical study, expected to commence in 2024

https://www.globenewswire.com/news-release/2024/01/29/2818876/0/en/Palisade-Bio-Announces-Positive-Preclinical-Data-of-Lead-Program-PALI-2108-at-the-2024-Crohn-s-Colitis-Congress.html